Compare HLN & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | ALC |
|---|---|---|
| Founded | 2022 | 1945 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 39.0B |
| IPO Year | N/A | N/A |
| Metric | HLN | ALC |
|---|---|---|
| Price | $9.85 | $79.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $88.29 |
| AVG Volume (30 Days) | ★ 7.5M | 1.2M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.84% | 0.27% |
| EPS Growth | ★ 41.64 | N/A |
| EPS | 0.23 | ★ 2.10 |
| Revenue | ★ $15,096,588,575.00 | $10,185,000,000.00 |
| Revenue This Year | $1.51 | $5.76 |
| Revenue Next Year | $4.67 | $7.24 |
| P/E Ratio | ★ $20.80 | $37.39 |
| Revenue Growth | N/A | ★ 4.34 |
| 52 Week Low | $8.71 | $71.55 |
| 52 Week High | $11.42 | $99.20 |
| Indicator | HLN | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 48.87 | 48.52 |
| Support Level | $9.71 | $78.78 |
| Resistance Level | $10.03 | $81.65 |
| Average True Range (ATR) | 0.13 | 1.54 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 24.17 | 44.10 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.